Related Experiment Video
Updated: Jun 4, 2026
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
Published on: March 18, 2015
Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects
1Vernadsky Institute of Geochemistry and Analytical Chemistry, Russian Academy of Sciences, Moscow, Russia. andrei.timerbaev@univie.ac.at
Abstract:
Gallium-based anticancer chemotherapeutics are appreciably progressing in clinical studies. A steady interest of drug developers and clinicians in gallium compounds is due to a proven ability of gallium cations to inhibit tumour growth, on the one hand, and enhanced bioavailability and moderate toxicity provided by the conversion of gallium into chelate complexes, on the other. One of the complexes suitable for a more convenient oral administration is tris(8-quinolinolato)gallium(iii) (KP46). Nominated from a range of gallium complexes for the clinical stage of development, KP46 has finished phase I trials with the outcome of promising tolerability and evidence of clinical activity in renal cell carcinoma. Therefore, there is obviously a need to codify and critically evaluate the continuing advances in the emergence of KP46 as a lead-drug candidate. Additionally, many questions remain unanswered regarding the relevant biological reactivity, modes of delivery and action and potential cell target(s) of KP46. The timely publication of the present review is also an attempt to shed light on these pertinent drug assets and to accelerate research activities towards further clinical development of KP46.
Insights
Tris(8-quinolinolato)gallium(iii) (KP46) shows promise as an oral gallium-based chemotherapy. Phase I trials indicate good tolerability and activity in renal cell carcinoma, warranting further research.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Gallium compounds demonstrate antitumor potential by inhibiting tumor growth.
- Chelation of gallium enhances bioavailability and reduces toxicity for therapeutic applications.
- Tris(8-quinolinolato)gallium(iii) (KP46) is an orally administered gallium complex developed for cancer treatment.
Purpose of the Study:
- To review and evaluate the development of KP46 as a potential anticancer drug candidate.
- To address unanswered questions regarding KP46's biological activity, delivery, and mechanisms of action.
- To stimulate further research for the clinical advancement of KP46.
Main Methods:
- Review of existing literature on gallium-based chemotherapeutics and KP46.
- Analysis of Phase I clinical trial data for KP46 in renal cell carcinoma.
- Critical evaluation of KP46's properties and potential therapeutic applications.
Main Results:
- KP46 has successfully completed Phase I clinical trials.
- The trials demonstrated promising tolerability and evidence of clinical activity in renal cell carcinoma patients.
- KP46 exhibits potential as a lead drug candidate for cancer therapy.
Conclusions:
- KP46 represents a significant advancement in gallium-based anticancer chemotherapy.
- Further investigation into KP46's biological reactivity and mechanisms is crucial for its development.
- Continued research is essential to accelerate the clinical progression of KP46.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
